Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer
Background: There is a lack of biomarkers for predicting the efficacy of immunotherapy in triple-negative breast cancer (TNBC). Hence, we constructed an immune risk score (IRS) model to predict the prognosis of patients with TNBC and evaluate those who are sensitive to immunotherapy.Methods: The rib...
Main Authors: | Xiaorui Sun, Tiansong Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.1067254/full |
Similar Items
-
Advances in immunotherapy for triple-negative breast cancer
by: Yang Liu, et al.
Published: (2023-09-01) -
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
by: Liying Li, et al.
Published: (2023-01-01) -
Components of the tumor immune microenvironment based on m‐IHC correlate with prognosis and subtype of triple‐negative breast cancer
by: Luyi Lin, et al.
Published: (2023-12-01) -
Fat Biology in Triple-Negative Breast Cancer: Immune Regulation, Fibrosis, and Senescence
by: Chae Min Lee, et al.
Published: (2023-12-01) -
Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer
by: Flavia Jacobs, et al.
Published: (2023-05-01)